KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Non-Current Debt (2016 - 2025)

Amgen has reported Non-Current Debt over the past 17 years, most recently at $50.0 billion for Q4 2025.

  • Quarterly results put Non-Current Debt at $50.0 billion for Q4 2025, down 11.57% from a year ago — trailing twelve months through Dec 2025 was $50.0 billion (down 11.57% YoY), and the annual figure for FY2025 was $50.0 billion, down 11.57%.
  • Non-Current Debt for Q4 2025 was $50.0 billion at Amgen, down from $52.4 billion in the prior quarter.
  • Over the last five years, Non-Current Debt for AMGN hit a ceiling of $63.2 billion in Q4 2023 and a floor of $28.5 billion in Q2 2021.
  • Median Non-Current Debt over the past 5 years was $53.1 billion (2025), compared with a mean of $47.8 billion.
  • Biggest five-year swings in Non-Current Debt: decreased 16.63% in 2021 and later soared 69.11% in 2023.
  • Amgen's Non-Current Debt stood at $33.2 billion in 2021, then increased by 12.44% to $37.4 billion in 2022, then soared by 69.11% to $63.2 billion in 2023, then dropped by 10.48% to $56.5 billion in 2024, then fell by 11.57% to $50.0 billion in 2025.
  • The last three reported values for Non-Current Debt were $50.0 billion (Q4 2025), $52.4 billion (Q3 2025), and $53.8 billion (Q2 2025) per Business Quant data.